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early enough to dramatically alter the establishment of the HIV reser-
voir. To better deﬁne the impact of ART on the reservoir, Ananworanich
and colleagues constructed two prospective cohorts of high-risk HIV-





Cell-associated HIV DNAThe case of the “Berlin Patient” is well-known. In 2007, an HIV-
infected adult with leukemia underwent allogeneic hematopoietic
stem cell transplant and was cured of his cancer (Hutter et al., 2009).
As the donor was homozygous for the CCR5Δ32 deletion (which
makes CD4+ T cells difﬁcult to infect with HIV), the repopulated
immune system lacked any detectable HIV and the patient has been
apparently been cured. Two subsequent allogeneic transplants
performed under potent ART (which protected the donor cells from
de novo infection) resulted in a dramatic reduction in the frequency of
cells harboring replication-competent HIV (generally referred to as the
HIV “reservoir”) (Henrich et al., 2014). This was not enough to cure
these two patients, however, as both individuals experienced a delayed
but robust rebound in viremia after stopping therapy. A true cure will
likely require complete eradication of the entire reservoir of HIV. This
is a formidable challenge.
Fortunately, a complete “sterilizing” cure may not be needed. Some
people are able to control replication-competent HIV in the absence of
therapy (“elite controllers”) or after stopping therapy (“post-treatment
controllers”). Extensive research over the past two decades has shown
this degree of control requires both a powerful HIV-speciﬁc immune
response and a low HIV reservoir size. The former may be achieved
with vaccines and other immunotherapies. The latter may be achieved
with “shock and kill” strategies and/or starting ART very early, before
the reservoir is fully established.
Early initiation of ART decreases the size of theHIV reservoir (Cheret
et al., 2015; Jain et al., 2013) and has clear beneﬁts on preventing AIDSm.2016.07.024.
. This is an open access article underand non-AIDS-related morbidity, but it is yet unclear how early is
describe the outcomes in those who were diagnosed early and not
treated (RV217, n = 17) and those who were diagnosed early and
treated almost immediately (RV254, n = 71) (Ananworanich et al.,
2016).
In the untreated state, the level of viremia (plasma HIV RNA levels)
reaches a well-characterized and highly informative “set-point” about
two months after the start of the infection (Robb et al., 2016). As now
described by Ananworanich and colleagues, the frequency of cells
harboring HIV DNA (an estimate of the reservoir size) closely follows
these same kinetics. The estimated reservoir size rises rapidly during
the ﬁrst fewweeks of the infection. At about the time HIV RNA becomes
detectable, the reservoir size begins to increase dramatically, with an
apparent 100-fold increase over the next two weeks, peaking approxi-
mately four weeks after HIV was acquired. Since effective ART blunts
HIV spread, achieving a durable and sustained reduction in the reservoir
size will require that ART be initiated during this critical phase. Indeed,
as shown in the current study, early ART resulted in an approximate
300-fold reduction in the reservoir size, as compared to what would
likely had happened had therapy not been started.
As acknowledged by the authors, the current study has a few limita-
tions. The exact duration of infection for many of the participants was
not known.Also, the reservoirmeasurement usedwas at best imprecise.
Most of the measured HIV DNA carries lethal mutations and/or
deletions and hence may not be clinically relevant. These measures
are assumed to be a surrogate for the size of the true reservoir (deﬁned
as virus that can replicate) but this may not be true (Eriksson et al.,
2013). Finally, although the frequency of cells harboring HIV DNA in
the cohort achieved a stable level after several weeks, it remains
unknown as to whether a true “set-point” is achieved. Careful analyses
of individual trajectories will be required to determine if a set-point
occurs as has been show for other markers, including HIV RNA
(Mellors et al., 1997) and perhaps T cell activation (Deeks et al., 2004).
It remains to be deﬁned as to whether the very early HIV DNA “set-
point” may contribute to persistent long-term consequences, such as
continued altered CD4/CD8 ratios, chronic inﬂammation, tissue ﬁbrosis,
and clinical outcomes. Though Ananworanich and colleagues did not
evaluate tissue-based viral measures where most of the latent HIVthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tially infectious) virus, levels of total HIV DNA in blood immediately
prior to treatment interruption have been shown to predict time to
viral rebound in ART-suppressed patients (Williams et al., 2014). There-
fore, their ﬁndings may have practical implications on the estimated
probability of achieving long-term remission off ART in those who are
diagnosed and treated during acute HIV infection.
These ﬁndings also highlight the importance of several ambitious
strategies, such as the “Getting to Zero” campaign being pursued in
San Francisco, which aims to rapidly identify HIV-infected individuals
- even prior to symptoms (i.e., peak viremia and viral set-point). Results
from this study suggest that such aggressive strategies might have
meaningful impact in markedly altering the size of the HIV reservoir if
acute infection is diagnosed and treated aggressively.
Conﬂicts of interest
The authors do not have a commercial or other association that
might pose a conﬂict of interest.
References
Ananworanich, J., Chomont, N., Eller, L.A., Kroon, E., Tovanabutra, S., Bose, M., Nau, M.,
Fletcher, J.L., Tipsuk, S., Vandergeeten, C., O'connell, R.J., Pinyakorn, S., Michael, N.,
Phanuphak, N., Robb, M.L., 2016. HIV DNA set point is rapidly established in acute
HIV infection and dramatically reduced by early ART. EBioMedicine 11, 68–72.
Cheret, A., Bacchus-Souffan, C., Avettand-Fenoel, V., Melard, A., Nembot, G., Blanc, C.,
Samri, A., Saez-Cirion, A., Hocqueloux, L., Lascoux-Combe, C., Allavena, C., Goujard,
C., Valantin, M.A., Leplatois, A., Meyer, L., Rouzioux, C., Autran, B., 2015. Combined
ART started during acute HIV infection protects central memory CD4+ T cells and
can induce remission. J. Antimicrob. Chemother. 70, 2108–2120.Deeks, S.G., Kitchen, C.M., Liu, L., Guo, H., Gascon, R., Narvaez, A.B., Hunt, P., Martin, J.N.,
Kahn, J.O., Levy, J., Mcgrath, M.S., Hecht, F.M., 2004. Immune activation set point
during early HIV infection predicts subsequent CD4+ T-cell changes independent of
viral load. Blood 104, 942–947.
Eriksson, S., Graf, E.H., Dahl, V., Strain, M.C., Yukl, S.A., Lysenko, E.S., Bosch, R.J., Lai, J.,
Chioma, S., Emad, F., Abdel-Mohsen, M., Hoh, R., Hecht, F., Hunt, P., Somsouk, M.,
Wong, J., Johnston, R., Siliciano, R.F., Richman, D.D., O'doherty, U., Palmer, S., Deeks,
S.G., Siliciano, J.D., 2013. Comparative analysis of measures of viral reservoirs in
HIV-1 eradication studies. PLoS Pathog. 9, e1003174.
Henrich, T.J., Hanhauser, E., Marty, F.M., Sirignano, M.N., Keating, S., Lee, T.H., Robles, Y.P.,
Davis, B.T., Li, J.Z., Heisey, A., Hill, A.L., Busch, M.P., Armand, P., Soiffer, R.J., Altfeld, M.,
Kuritzkes, D.R., 2014. Antiretroviral-free HIV-1 remission and viral rebound after
allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med.
Hutter, G., Nowak, D., Mossner, M., Ganepola, S., Mussig, A., Allers, K., Schneider, T.,
Hofmann, J., Kucherer, C., Blau, O., Blau, I.W., Hofmann, W.K., Thiel, E., 2009. Long-
term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl.
J. Med. 360, 692–698.
Jain, V., Hartogensis, W., Bacchetti, P., Hunt, P.W., Hatano, H., Sinclair, E., Epling, L., Lee,
T.H., Busch, M.P., Mccune, J.M., Pilcher, C.D., Hecht, F.M., Deeks, S.G., 2013.
Antiretroviral therapy initiated within 6 months of HIV infection is associated with
lower T-cell activation and smaller HIV reservoir size. J. Infect. Dis. 208, 1202–1211.
Mellors, J.W., Munoz, A., Giorgi, J.V., Margolick, J.B., Tassoni, C.J., Gupta, P., Kingsley, L.A.,
Todd, J.A., Saah, A.J., Detels, R., Phair, J.P., Rinaldo JR., C.R., 1997. Plasma viral load
and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med.
126, 946–954.
Robb, M.L., Eller, L.A., Kibuuka, H., Rono, K., Maganga, L., Nitayaphan, S., Kroon, E., Sawe,
F.K., Sinei, S., Sriplienchan, S., Jagodzinski, L.L., Malia, J., Manak, M., De Souza, M.S.,
Tovanabutra, S., Sanders-Buell, E., Rolland, M., Dorsey-Spitz, J., Eller, M.A., Milazzo,
M., Li, Q., Lewandowski, A., Wu, H., Swann, E., O'Connell, R.J., Peel, S., Dawson, P.,
Kim, J.H., Michael, N.L., 2016. Prospective study of acute HIV-1 infection in adults in
East Africa and Thailand. N. Engl. J. Med. 374, 2120–2130.
Williams, J.P., Hurst, J., Stohr, W., Robinson, N., Brown, H., Fisher, M., Kinloch, S., Cooper,
D., Schechter, M., Tambussi, G., Fidler, S., Carrington, M., Babiker, A., Weber, J.,
Koelsch, K.K., Kelleher, A.D., Phillips, R.E., Frater, J., Investigators, S.P., 2014. HIV-1
DNA predicts disease progression and post-treatment virological control. Elife 3,
e03821.
